Osteosarcoma cells promote the production of pro-tumor cytokines in mesenchymal stem cells by inhibiting their osteogenic differentiation through the TGF-β/Smad2/3 pathway

Experimental Cell Research

Volumn 320, Issue 1, 2014, Pages 164-173

  Tu, Bing ^a   Peng, Zhao Xiang ^a,b   Fan, Qi Ming ^a   Du, Lin ^a   Yan, Wei ^a   Tang, Ting Ting ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Ningbo Medical Treatment Center Lihuili Hospital   (China)

Author keywords

Cytokines; Mesenchymal stem cells; Osteogenic differentiation; TGF Smad2 3 pathway; Tumor microenvironment

Indexed keywords

BETA CATENIN; DICKKOPF 1 PROTEIN; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; OSTEOCALCIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84888197660     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.10.013     Document Type: Article

References (38)

1. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
2. Polyak K., Haviv I., Campbell I.G. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009, 25:30-38.
3. Calorini L., Bianchini F. Environmental control of invasiveness and metastatic dissemination of tumor cells: the role of tumor cell-host cell interactions. Cell Commun. Signal. 2010, 8:24.
4. Bergfeld S.A., DeClerck Y.A. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev. 2010, 29:249-261.
5. Spaeth E.L., Dembinski J.L., Sasser A.K., Watson K., Klopp A., Hall B., Andreeff M., Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4:e4992.
6. Xu W.T., Bian Z.Y., Fan Q.M., Li G., Tang T.T. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett. 2009, 281:32-41.
7. Bouffi C., Bony C., Courties G., Jorgensen C., Noel D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 2010, 5:e14247.
8. Klopp A.H., Gupta A., Spaeth E., Andreeff M., Marini F. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?. Stem Cells 2011, 29:11-19.
9. Tu B., Du L., Fan Q.M., Tang Z., Tang T.T. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett. 2012, 325:80-88.
10. Yang L., Pang Y., Moses H.L. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010, 31:220-227.
11. Bierie B., Moses H.L. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev. 2010, 21:49-59.
12. Inman G.J. Switching TGFbeta from a tumor suppressor to a tumor promoter. Curr. Opin. Genet. Dev. 2011, 21:93-99.
13. Ikushima H., Todo T., Ino Y., Takahashi M., Miyazawa K., Miyazono K. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 2009, 5:504-514.
14. Gregory P.A., Bracken C.P., Smith E., Bert A.G., Wright J.A., Roslan S., Morris M., Wyatt L., Farshid G., Lim Y.Y., Lindeman G.J., Shannon M.F., Drew P.A., Khew-Goodall Y., Goodall G.J. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol. Biol. Cell 2011, 22:1686-1698.
15. James D., Levine A.J., Besser D., Hemmati-Brivanlou A. TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 2005, 132:1273-1282.
16. Meulmeester E., Ten Dijke P. The dynamic roles of TGF-beta in cancer. J. Pathol. 2011, 223:205-218.
17. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
18. Seuntjens E., Umans L., Zwijsen A., Sampaolesi M., Verfaillie C.M., Huylebroeck D. Transforming growth factor type beta and Smad family signaling in stem cell function. Cytokine Growth Factor Rev. 2009, 20:449-458.
19. Maeda S., Hayashi M., Komiya S., Imamura T., Miyazono K. Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J. 2004, 23:552-563.
20. Letamendia A., Labbe E., Attisano L. Transcriptional regulation by Smads: crosstalk between the TGF-beta and Wnt pathways. J. Bone Joint Surg. Am. A 2001, 83(Suppl. 1):S31-39.
21. Zhou S. TGF-beta regulates beta-catenin signaling and osteoblast differentiation in human mesenchymal stem cells. J. Cell. Biochem. 2011, 112:1651-1660.
22. Liu N., Shi S., Deng M., Tang L., Zhang G., Ding B., Liu W., Liu Y., Shi H., Liu L., Jin Y. High levels of beta-catenin signaling reduce osteogenic differentiation of stem cells in inflammatory microenvironments through inhibition of the noncanonical Wnt pathway. J. Bone Miner. Res. 2011, 26:2082-2095.
23. Bian Z.Y., Fan Q.M., Li G., Xu W.T., Tang T.T. Human mesenchymal stem cells promote growth of osteosarcoma: involvement of interleukin-6 in the interaction between human mesenchymal stem cells and Saos-2. Cancer Sci. 2010, 101:2554-2560.
24. Broadhead M.L., Clark J.C., Myers D.E., Dass C.R., Choong P.F. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011, 2011:959248.
25. Shangguan L., Ti X., Krause U., Hai B., Zhao Y., Yang Z., Liu F. Inhibition of TGF-beta/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects. Stem Cells 2012, 30:2810-2819.
26. Takeuchi K., Abe M., Hiasa M., Oda A., Amou H., Kido S., Harada T., Tanaka O., Miki H., Nakamura S., Nakano A., Kagawa K., Yata K., Ozaki S., Matsumoto T. Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One 2010, 5:e9870.
27. Ferrari G., Cook B.D., Terushkin V., Pintucci G., Mignatti P. Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J. Cell. Physiol. 2009, 219:449-458.
28. Kolosova I., Nethery D., Kern J.A. Role of Smad2/3 and p38 MAP kinase in TGF-beta1-induced epithelial-mesenchymal transition of pulmonary epithelial cells. J. Cell. Physiol. 2011, 226:1248-1254.
29. Alliston T., Choy L., Ducy P., Karsenty G., Derynck R. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J. 2001, 20:2254-2272.
30. Matsumoto Y., Otsuka F., Hino J., Miyoshi T., Takano M., Miyazato M., Makino H., Kangawa K. Bone morphogenetic protein-3b (BMP-3b) inhibits osteoblast differentiation via Smad2/3 pathway by counteracting Smad1/5/8 signaling. Mol. Cell. Endocrinol. 2012, 350:78-86.
31. Liu G., Vijayakumar S., Grumolato L., Arroyave R., Qiao H., Akiri G., Aaronson S.A. Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells. J. Cell Biol. 2009, 185:67-75.
32. Boland G.M., Perkins G., Hall D.J., Tuan R.S. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J. Cell. Biochem. 2004, 93:1210-1230.
33. Cho H.H., Kim Y.J., Kim S.J., Kim J.H., Bae Y.C., Ba B., Jung J.S. Endogenous Wnt signaling promotes proliferation and suppresses osteogenic differentiation in human adipose derived stromal cells. Tissue Eng. 2006, 12:111-121.
34. Luu H.H., Song W.X., Luo X., Manning D., Luo J., Deng Z.L., Sharff K.A., Montag A.G., Haydon R.C., He T.C. Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J. Orthop. Res. 2007, 25:665-677.
35. Sugano Y., Matsuzaki K., Tahashi Y., Furukawa F., Mori S., Yamagata H., Yoshida K., Matsushita M., Nishizawa M., Fujisawa J., Inoue K. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells. Oncogene 2003, 22:2309-2321.
36. Yao Z., Fenoglio S., Gao D.C., Camiolo M., Stiles B., Lindsted T., Schlederer M., Johns C., Altorki N., Mittal V., Kenner L., Sordella R. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:15535-15540.
37. Cui J., Jiang W., Wang S., Wang L., Xie K. Role of Wnt/beta-catenin signaling in drug resistance of pancreatic cancer. Curr. Pharm. Des. 2012, 18:2464-2471.
38. Easwaran V., Lee S.H., Inge L., Guo L., Goldbeck C., Garrett E., Wiesmann M., Garcia P.D., Fuller J.H., Chan V., Randazzo F., Gundel R., Warren R.S., Escobedo J., Aukerman S.L., Taylor R.N., Fantl W.J. beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res. 2003, 63:3145-3153.